Biotechnology investors understand that their appetite for speculation brings both risk and reward, but it is likely that even the bravest stockpickers will be happy to leave 2014 behind.
Biotechnology investors understand that their appetite for speculation brings both risk and reward, but it is likely that even the bravest stockpickers will be happy to leave 2014 behind.
As Watermark Funds Management analyst Joshua Ross says: “It was a year littered with disasters."
Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
